| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| May 10, 2017 | LFCR Lifecore Biomedical, Inc. \de\ | Steele Gary T | Director | Sell | 26,708 | $14.00 | $373,912.00 | -24.4% | |
| May 10, 2017 | LFCR Lifecore Biomedical, Inc. \de\ | Steele Gary T | Director | Sell | 26,708 | $14.00 | $373,912.00 | -24.4% | |
| May 9, 2017 | LNTH Lantheus Holdings, Inc. | Burgstahler David F | Director, 10% Owner | Sell | 3,000,000 | $13.40 | $40,200,000.00 | -24.4% | |
| May 9, 2017 | LNTH Lantheus Holdings, Inc. | Schaffer Derace L | Director | Sell | 10,000 | $14.75 | $147,500.00 | -11.9% | |
| May 9, 2017 | PAHC Phibro Animal Health Corp | Dagger Thomas G | SVP, Gen Counsel And Corp Secr | Sell | 8,000 | $32.13 | $257,040.00 | -100% | |
| May 9, 2017 | LNTH Lantheus Holdings, Inc. | Avista Capital Partners Gp, LLC | 10% Owner | Sell | 3,000,000 | $13.40 | $40,200,000.00 | -24.4% | |
| May 9, 2017 | PAHC Phibro Animal Health Corp | Miller Larry Lee | Chief Operating Officer | Sell | 56,825 | $30.95 | $1,758,670.45 | -100% | |
| May 5, 2017 | NBIX Neurocrine Biosciences Inc | Nevinny Corinne H | Director | Sell | 5,000 | $53.98 | $269,900.00 | -12.6% | |
| May 4, 2017 | ALKS Alkermes Plc. | Cooke Shane62 | President, Alkermes Plc | Sell | 6,500 | $60.05 | $390,328.25 | -8.3% | |
| May 4, 2017 | LLY Eli Lilly & Co | Conterno Enrique A87 | SVP&Pres, Lillydiab &Lillyusa | Sell | 25,000 | $82.76 | $2,069,000.00 | -18.0% | |
| May 4, 2017 | PAHC Phibro Animal Health Corp | Miller Larry Lee | Chief Operating Officer | Sell | 18,953 | $30.13 | $571,123.98 | -100% | |
| May 2, 2017 | NBIX Neurocrine Biosciences Inc | Gorman Kevin Charles55 | Chief Executive Officer | Sell | 21,739 | $53.23 | $1,157,166.97 | -6.1% | |
| May 2, 2017 | NBIX Neurocrine Biosciences Inc | Grigoriadis Dimitri E. | Chief Research Officer | Sell | 10,000 | $55.00 | $550,000.00 | -7.8% | |
| May 1, 2017 | NBIX Neurocrine Biosciences Inc | Gano Kyle54 | Chief Business Development Off | Sell | 15,000 | $54.00 | $810,000.00 | -17.0% | |
| May 1, 2017 | ALKS Alkermes Plc. | Mitchell Paul J | Director | Sell | 1,500 | $58.74 | $88,110.00 | -15.8% | |
| May 1, 2017 | ALKS Alkermes Plc. | Cooke Shane62 | President, Alkermes Plc | Sell | 3,500 | $60.05 | $210,164.85 | -4.6% | |
| May 1, 2017 | PAHC Phibro Animal Health Corp | Miller Larry Lee | Chief Operating Officer | Sell | 14,780 | $30.13 | $445,253.05 | -100% | |
| Apr 25, 2017 | EGRX Eagle Pharmaceuticals, Inc. | Proquest Investments Iv, L.P. | 10% Owner | Sell | 54,180 | $88.38 | $4,788,481.95 | -76.6% | |
| Apr 24, 2017 | SUPN Supernus Pharmaceuticals, Inc. | Patrick Gregory S | VP, Chief Financial Officer | Sell | 54,000 | $32.37 | $1,747,872.00 | -99.6% | |
| Apr 24, 2017 | SUPN Supernus Pharmaceuticals, Inc. | Bhatt Padmanabh P.69 | Sr. VP Of Ip, CSO | Sell | 11,806 | $32.59 | $384,762.26 | -20.6% | |
| Apr 17, 2017 | ALKS Alkermes Plc. | Ehrich Elliot | EVP, R&D &CMO, Alkermes, Inc. | Sell | 10,000 | $56.60 | $565,986.00 | -15.4% | |
| Apr 12, 2017 | NBIX Neurocrine Biosciences Inc | Lippoldt Darin60 | Chief Legal Officer | Sell | 13,065 | $50.42 | $658,773.93 | -33.0% | |
| Apr 12, 2017 | NBIX Neurocrine Biosciences Inc | Lloyd-Smith Malcolm49 | Chief Regulatory Officer | Sell | 13,065 | $50.42 | $658,773.93 | -33.2% | |
| Apr 12, 2017 | NBIX Neurocrine Biosciences Inc | Gano Kyle54 | Chief Business Development Off | Sell | 13,065 | $50.42 | $658,773.93 | -8.2% | |
| Apr 12, 2017 | NBIX Neurocrine Biosciences Inc | Grigoriadis Dimitri E. | Chief Research Officer | Sell | 13,065 | $50.42 | $658,773.93 | -4.9% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.